Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large BCell Lymphoma: A Real World Analysis from 21 US Centers

BLOOD(2023)

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要